TriangleAsciminib 40 MG (NCT04838041)
Asciminib 40 MG trial for Chronic Phase Chronic Myelogenous Leukemia (NCT04838041). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with chronic-phase chronic myeloid leukemia after one failed attempt to stop treatment. They must regain deep molecular response after restarting the same drug; T315I mutations are excluded.
The idea: asciminib blocks BCR-ABL1 signaling. It is given alone or with imatinib, nilotinib, or dasatinib for at least a year. Patients meeting response criteria attempt supervised treatment stop, with molecular testing. Researchers measure remission without treatment one year later.
This phase 2 study plans 51 patients. Ehab Atallah leads at the Medical College of Wisconsin; five US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.